On July 28, 2020,
the company announced it secured a Letter of Interest (LOI) from the U.S. International Development Finance Corporation (DFC) to establish Kodak Pharmaceuticals with a $765M loan. Kodak Pharmaceuticals will “produce up to 25 percent of active pharmaceutical ingredients used in non-biologic, non-antibacterial, generic pharmaceuticals…” The DFC describes itself as “America’s development bank.” As such, the DFC invests in private companies to support unaddressed, under-served, and emerging market needs in the U.S. In the case of Eastman Kodak,
the DFC explained:
“Kodak Pharmaceuticals will produce critical pharmaceutical components that have been identified as essential but have lapsed into chronic national shortage, as defined by the Food and Drug Administration (FDA). Although Americans consume approximately 40 percent of the world’s supply of bulk components used to produce generic pharmaceutics, only 10 percent of these materials are manufactured in the United States … DFC’s loan will accelerate Kodak’s time to market by supporting startup costs needed to repurpose and expand the company’s existing facilities …”